Assessing The Impact Of Roche's Disappointing APHINITY Trial Results

Roche's much-awaited APHINITY trial results did not impress the market, and the company's stock took a beating this week. Roche was banking on the Herceptin + Perjeta combination to meaningfully outperform Herceptin in the treatment of breast cancer.